Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)

Paul M Ridker; Jean G MacFadyen; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn; JUPITER Study Group

doi:10.1161/CIRCOUTCOMES.109.848473

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)

Paul M Ridker, Jean G MacFadyen, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Børge G Nordestgaard, James Shepherd, James T Willerson, Robert J Glynn, JUPITER Study Group

125 Citationer (Scopus)

Abstract

As recently demonstrated, random allocation to rosuvastatin results in large relative risk reductions for first cardiovascular events among apparently healthy men and women with low levels of low-density lipoprotein cholesterol but elevated levels of high-sensitivity C-reactive protein. However, whether the absolute risk reduction among such individuals justifies wide application of statin therapy in primary prevention is a controversial issue with broad policy and public health implications.

Originalsprog	Engelsk
Tidsskrift	Circulation. Cardiovascular Quality and Outcomes
Vol/bind	2
Udgave nummer	6
Sider (fra-til)	616-23
Antal sider	8
ISSN	1941-7713
DOI	https://doi.org/10.1161/CIRCOUTCOMES.109.848473
Status	Udgivet - 1 nov. 2009

Adgang til dokumentet

10.1161/CIRCOUTCOMES.109.848473

Fingeraftryk

Dyk ned i forskningsemnerne om 'Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Ridker, P. M., MacFadyen, J. G., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., Glynn, R. J., & JUPITER Study Group (2009). Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality and Outcomes, 2(6), 616-23. https://doi.org/10.1161/CIRCOUTCOMES.109.848473

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). / Ridker, Paul M; MacFadyen, Jean G; Fonseca, Francisco A H et al.
I: Circulation. Cardiovascular Quality and Outcomes, Bind 2, Nr. 6, 01.11.2009, s. 616-23.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Ridker, PM, MacFadyen, JG, Fonseca, FAH, Genest, J, Gotto, AM, Kastelein, JJP, Koenig, W, Libby, P, Lorenzatti, AJ, Nordestgaard, BG, Shepherd, J, Willerson, JT, Glynn, RJ & JUPITER Study Group 2009, 'Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)', Circulation. Cardiovascular Quality and Outcomes, bind 2, nr. 6, s. 616-23. https://doi.org/10.1161/CIRCOUTCOMES.109.848473

Ridker PM, MacFadyen JG, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality and Outcomes. 2009 nov. 1;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473

Ridker, Paul M ; MacFadyen, Jean G ; Fonseca, Francisco A H et al. / Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). I: Circulation. Cardiovascular Quality and Outcomes. 2009 ; Bind 2, Nr. 6. s. 616-23.

@article{84b92c3d23a849d1b778dde92a116687,

title = "Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)",

abstract = "As recently demonstrated, random allocation to rosuvastatin results in large relative risk reductions for first cardiovascular events among apparently healthy men and women with low levels of low-density lipoprotein cholesterol but elevated levels of high-sensitivity C-reactive protein. However, whether the absolute risk reduction among such individuals justifies wide application of statin therapy in primary prevention is a controversial issue with broad policy and public health implications.",

author = "Ridker, {Paul M} and MacFadyen, {Jean G} and Fonseca, {Francisco A H} and Jacques Genest and Gotto, {Antonio M} and Kastelein, {John J P} and Wolfgang Koenig and Peter Libby and Lorenzatti, {Alberto J} and Nordestgaard, {B{\o}rge G} and James Shepherd and Willerson, {James T} and Glynn, {Robert J} and {JUPITER Study Group}",

year = "2009",

month = nov,

day = "1",

doi = "10.1161/CIRCOUTCOMES.109.848473",

language = "English",

volume = "2",

pages = "616--23",

journal = "Circulation. Cardiovascular Quality and Outcomes",

issn = "1941-7713",

publisher = "Lippincott Williams & Wilkins",

number = "6",

}

TY - JOUR

T1 - Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)

AU - Ridker, Paul M

AU - MacFadyen, Jean G

AU - Fonseca, Francisco A H

AU - Genest, Jacques

AU - Gotto, Antonio M

AU - Kastelein, John J P

AU - Koenig, Wolfgang

AU - Libby, Peter

AU - Lorenzatti, Alberto J

AU - Nordestgaard, Børge G

AU - Shepherd, James

AU - Willerson, James T

AU - Glynn, Robert J

AU - JUPITER Study Group

PY - 2009/11/1

Y1 - 2009/11/1

N2 - As recently demonstrated, random allocation to rosuvastatin results in large relative risk reductions for first cardiovascular events among apparently healthy men and women with low levels of low-density lipoprotein cholesterol but elevated levels of high-sensitivity C-reactive protein. However, whether the absolute risk reduction among such individuals justifies wide application of statin therapy in primary prevention is a controversial issue with broad policy and public health implications.

AB - As recently demonstrated, random allocation to rosuvastatin results in large relative risk reductions for first cardiovascular events among apparently healthy men and women with low levels of low-density lipoprotein cholesterol but elevated levels of high-sensitivity C-reactive protein. However, whether the absolute risk reduction among such individuals justifies wide application of statin therapy in primary prevention is a controversial issue with broad policy and public health implications.

U2 - 10.1161/CIRCOUTCOMES.109.848473

DO - 10.1161/CIRCOUTCOMES.109.848473

M3 - Journal article

C2 - 20031900

SN - 1941-7713

VL - 2

SP - 616

EP - 623

JO - Circulation. Cardiovascular Quality and Outcomes

JF - Circulation. Cardiovascular Quality and Outcomes

IS - 6

ER -